A33scFv-cytosine deaminase: a recombinant protein construct for antibody-directed enzyme-prodrug therapy.
A recombinant fusion protein of colon carcinoma binding A33 single chain antibody with cytosine deaminase displayed specific antigen binding and enzyme activity in surface plasmon resonance and is catalytic activity assay. In vitro, it selectively increased the toxicity of 5-FC to A33 antigen-positive cells by 300-fold, demonstrating the potency of this ADEPT strategy.
Deckert
P M
PM
Medizinische Klinik III, Universitätsklinikum Benjamin Franklin, Freie Universität Berlin, Germany. deckert@medizin.fu-berlin.de
Renner
C
C
Cohen
L S
LS
Jungbluth
A
A
Ritter
G
G
Bertino
J R
JR
Old
L J
LJ
Welt
S
S
D000951:Antigens, Neoplasm; D002384:Catalysis; D043525:Cytosine Deaminase; D004926:Escherichia coli / Q000235:genetics; D006801:Humans; D007128:Immunoglobulin Fragments; D007135:Immunoglobulin Variable Region; D008562:Membrane Glycoproteins / Q000276:immunology* / Q000494:pharmacology; D009700:Nucleoside Deaminases / Q000737:chemistry / Q000276:immunology / Q000494:pharmacology*; D016133:Polymerase Chain Reaction; D011993:Recombinant Fusion Proteins / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
D000951:Antigens, Neoplasm; C104258:GPA33 protein, human; D007128:Immunoglobulin Fragments; D007135:Immunoglobulin Variable Region; D008562:Membrane Glycoproteins; D011993:Recombinant Fusion Proteins; D009700:Nucleoside Deaminases; D043525:Cytosine Deaminase